MX2024011338A - Moléculas bifuncionales pequeñas para dirigir la degradación selectiva de proteínas circulantes. - Google Patents

Moléculas bifuncionales pequeñas para dirigir la degradación selectiva de proteínas circulantes.

Info

Publication number
MX2024011338A
MX2024011338A MX2024011338A MX2024011338A MX2024011338A MX 2024011338 A MX2024011338 A MX 2024011338A MX 2024011338 A MX2024011338 A MX 2024011338A MX 2024011338 A MX2024011338 A MX 2024011338A MX 2024011338 A MX2024011338 A MX 2024011338A
Authority
MX
Mexico
Prior art keywords
receptor
small molecules
crbm
moiety
target
Prior art date
Application number
MX2024011338A
Other languages
English (en)
Spanish (es)
Inventor
David Spiegel
David Caianiello
Mengwen Zhang
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/695,645 external-priority patent/US12485178B2/en
Application filed by Univ Yale filed Critical Univ Yale
Publication of MX2024011338A publication Critical patent/MX2024011338A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024011338A 2022-03-15 2024-09-13 Moléculas bifuncionales pequeñas para dirigir la degradación selectiva de proteínas circulantes. MX2024011338A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/695,645 US12485178B2 (en) 2018-04-09 2022-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins
PCT/US2023/064470 WO2023178202A2 (en) 2022-03-15 2023-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins

Publications (1)

Publication Number Publication Date
MX2024011338A true MX2024011338A (es) 2024-12-06

Family

ID=88024440

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011338A MX2024011338A (es) 2022-03-15 2024-09-13 Moléculas bifuncionales pequeñas para dirigir la degradación selectiva de proteínas circulantes.

Country Status (8)

Country Link
EP (1) EP4493222A2 (https=)
JP (1) JP2025509730A (https=)
KR (1) KR20240166514A (https=)
CN (1) CN119255822A (https=)
AU (1) AU2023236291A1 (https=)
IL (1) IL315579A (https=)
MX (1) MX2024011338A (https=)
WO (1) WO2023178202A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4370157A1 (en) 2021-07-14 2024-05-22 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
WO2025219911A1 (en) * 2024-04-16 2025-10-23 Biohaven Therapeutics Ltd. Treatment of diseases with monoclonal antibody drugs and molecular degraders
WO2025248469A1 (en) * 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. TREATMENT OF IgG-RELATED DISEASES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
WO2019199621A1 (en) * 2018-04-09 2019-10-17 Yale University Bi-functional molecules to degrade circulating proteins
EP3773727A4 (en) * 2018-04-09 2022-05-04 Yale University BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS
AU2019404061A1 (en) * 2018-12-19 2021-07-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules for lysosomal targeting and related compositions and methods
WO2021155317A1 (en) * 2020-01-31 2021-08-05 Avilar Therapeutics, Inc. Asgpr-binding compounds for the degradation of extracellular proteins

Also Published As

Publication number Publication date
WO2023178202A2 (en) 2023-09-21
JP2025509730A (ja) 2025-04-11
EP4493222A2 (en) 2025-01-22
WO2023178202A3 (en) 2023-10-26
AU2023236291A1 (en) 2024-10-03
KR20240166514A (ko) 2024-11-26
CN119255822A (zh) 2025-01-03
IL315579A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
MX2024011338A (es) Moléculas bifuncionales pequeñas para dirigir la degradación selectiva de proteínas circulantes.
MX2025012651A (es) Moléculas pequeñas bifuncionales para dirigirse a la degradación selectiva de proteínas circulantes
Brandina et al. Enolase takes part in a macromolecular complex associated to mitochondria in yeast
AR080942A1 (es) Produccion de proteinas heteromultimericas
AR127516A2 (es) VARIANTES DE Fc Y MÉTODOS PARA SU PRODUCCIÓN
Bligny et al. Regulation of plastid rDNA transcription by interaction of CDF2 with two different RNA polymerases
DK1652258T3 (da) Membran-elektrode-enhed til vandelektrolyse
DK1846974T3 (da) Membran-elektrode samlinger til brændstofceller, deres fremstilling og anvendelse og brændstofceller indeholdende disse
GB9822576D0 (en) Membrane
EA201000490A1 (ru) Антигенсвязывающие белки, связывающиеся с человеческим белком gm-csf
TW200735447A (en) Laminated electrolyte membrane for solid polymer fuel cells, membrane-electrode combine and fuel cells
PE20121530A1 (es) Inmunoglobulinas con dominio variable dual
BR122019022434B8 (pt) método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
AR048025A1 (es) Plantas con actividad aumentada de una enzima fosforilante del almidon
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
PT1166382E (pt) Fabricacao de celulas de combustivel tubulares modulos de celulas de combustivel elementos basicos e membranas permutadoras de ioes
WO2007142884A3 (en) Membranes electrode assemblies prepared from fluoropolymer dispersions
ATE537188T1 (de) Serumalbuminbindende proteine
Ramírez et al. Characterization of the single-subunit oligosaccharyltransferase STT3A from Trypanosoma brucei using synthetic peptides and lipid-linked oligosaccharide analogs
Jiang et al. Synthetic engineering of a new biocatalyst encapsulating [NiFe]-hydrogenases for enhanced hydrogen production
DK1931704T3 (da) Frembringelse og rensning af IL-29
MX2020000583A (es) Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados.
GB2464888A (en) Compositions and methods for detecting and modulating cell death by a translation regulated gene expression system
MX2023008909A (es) Proteínas de unión a psma y usos de estas.
CY1118782T1 (el) Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια